AXA1125与AXA1957在非酒精性脂肪性肝病中的安全性、耐受性及生物活性
这项为期16周的多中心、安慰剂对照、单盲、随机临床试验纳入102例非酒精性脂肪性肝病(NAFLD)受试者(其中40例合并2型糖尿病),评估AXA1125 24g、AXA1957 13.5g或20.3g每日两次给药的安全性、耐受性及生物活性。结果显示AXA1125在改善MRI-PDFF、HOMA-IR、ALT、K-18 M65、cT1等指标上活性优于AXA1957和安慰剂,且安全耐受良好。
要点
- AXA1125 24g每日两次治疗16周可显著降低MRI-PDFF、HOMA-IR、ALT、K-18 M65和cT1。
- AXA1125组达到MRI-PDFF下降≥30%、ALT下降≥17 IU/L、cT1下降≥80 ms的比例更高。
- AXA1125和AXA1957安全耐受良好,血脂和体重稳定。
核心结论
- AXA1125和AXA1957对NAFLD相关通路显示多靶点活性,AXA1125在16周内活性最强,值得在非酒精性脂肪性肝炎受试者中继续临床研究。
研究设计与样本
- 多中心、16周、安慰剂对照、单盲、随机临床试验,纳入102例NAFLD受试者(其中40例合并2型糖尿病),按是否合并2型糖尿病分层。
- 受试者接受AXA1125 24g、AXA1957 13.5g或20.3g、或安慰剂每日两次给药。
主要发现
- 第16周AXA1125组较基线变化 vs 安慰剂组:MRI-PDFF -22.9% vs -5.7%,HOMA-IR -4.4 vs +0.7,ALT -21.9% vs -7.2%,K-18 M65 -13.6% vs +20.1%,cT1 -69.6 vs +18.3 ms(P < 0.05),Pro-C3 -13.6% vs -3.6%。
- 第16周AXA1957 20.3g组较基线变化:MRI-PDFF -8.1%,HOMA-IR +8.4,ALT -20.7%,K-18 M65 6.6%,cT1 -34.7 ms,Pro-C3 -15.6%。
- AXA1125组达到MRI-PDFF下降≥30%、ALT下降≥17 IU/L、cT1下降≥80 ms的受试者比例更高。
- 研究产品安全且耐受良好,血脂和体重谱稳定。
关键数值与推荐
- AXA1125 24g每日两次,AXA1957 13.5g或20.3g每日两次,安慰剂每日两次。
- 主要代谢指标包括MRI-PDFF和HOMA-IR;纤维炎症标志物包括ALT、cT1、K-18 M65和Pro-C3。
临床怎么用
- AXA1125在NAFLD患者中显示出改善肝脏脂肪、胰岛素抵抗和纤维炎症标志物的潜力,但需进一步临床研究确认。
局限性
- 研究为单盲设计,样本量有限(102例),且为16周短期研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: AXA1125 and AXA1957 are novel, orally administered endogenous metabolic modulator compositions, specifically designed to simultaneously support multiple metabolic and fibroinflammatory pathways associated with nonalcoholic fatty liver disease (NAFLD). This study assessed safety, tolerability, and biologic activity of AXA1125 and AXA1957 in NAFLD. METHODS: In this multicenter, 16-week, placebo-controlled, single-blind, randomized clinical study in subjects with NAFLD stratified by type 2 diabetes, AXA1125 24 g, AXA1957 13.5 g or 20.3 g, or placebo was administered twice daily. Key metabolism (MRI-proton density fat fraction [MRI-PDFF] and homeostasis model assessment of insulin resistance [HOMA-IR]) and fibroinflammation markers (alanine aminotransferase [ALT], corrected T1 [cT1], keratin-18 [K-18] M65, and N-terminal type III collagen propeptide [Pro-C3]) were evaluated. Safety outcomes included adverse events and standard laboratory assessments. RESULTS: Baseline characteristics of the 102 enrolled subjects, including 40 with type 2 diabetes, were consistent with presumed nonalcoholic steatohepatitis. AXA1125 showed consistently greater biologic activity than AXA1957 or placebo. Week 16 changes from baseline with AXA1125 vs placebo: MRI-PDFF -22.9% vs -5.7%, HOMA-IR -4.4 vs +0.7, ALT -21.9% vs -7.2%, K-18 M65 -13.6% vs +20.1%, cT1 -69.6 vs +18.3 ms (P < 0.05), and Pro-C3 -13.6% vs -3.6%. Week 16 changes from baseline with AXA1957 20.3 g: MRI-PDFF -8.1%, HOMA-IR +8.4, ALT -20.7%, K-18 M65 6.6%, cT1 -34.7 ms, and Pro-C3 -15.6%. A greater proportion of subjects treated with AXA1125 achieved clinically relevant thresholds: ≥30% MRI-PDFF, ≥17-IU/L ALT, and ≥80-ms cT1 reductions at week 16. Study products were safe and well tolerated with stable lipid and weight profiles. DISCUSSION: Both compositions showed multitargeted activity on relevant NAFLD pathways. AXA1125 demonstrated the greatest activity over 16 weeks, warranting continued clinical investigation in nonalcoholic steatohepatitis subjects.
引用
- Harrison SA, Baum SJ, Gunn NT, et al. Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2021. PMID: 34382947. doi:10.14309/ajg.0000000000001375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。